Nicotinic Acetylcholine Receptor Subunit Variants Are Associated with Blood Pressure; Findings in the Old Order Amish and Replication in the Framingham Heart Study by McArdle, Patrick F. et al.
Boston University
OpenBU http://open.bu.edu
Department of Medicine MED: Medicine Papers
2008-7-14
Nicotinic Acetylcholine Receptor
Subunit Variants Are Associated
with Blood Pressure; Findings in the
Old Order Amish and Replication in
the Framingham Heart Study
McArdle, Patrick F, Sue Rutherford, Braxton D Mitchell, Coleen M Damcott, Ying
Wang, Vasan Ramachandran, Sandy Ott, Yen-Pei C Chang, Daniel Levy, Nanette
Steinle. "Nicotinic acetylcholine receptor subunit variants are associated with blood
pressure; findings in the Old Order Amish and replication in the Framingham Heart
Study" BMC Medical Genetics 9:67. (2008)
https://hdl.handle.net/2144/2516
Boston University
BioMed CentralBMC Medical Genetics
ssOpen AcceResearch article
Nicotinic acetylcholine receptor subunit variants are associated 
with blood pressure; findings in the Old Order Amish and 
replication in the Framingham Heart Study
Patrick F McArdle1, Sue Rutherford2, Braxton D Mitchell1, 
Coleen M Damcott1, Ying Wang1, Vasan Ramachandran3, Sandy Ott1, Yen-
Pei C Chang1, Daniel Levy4 and Nanette Steinle*1
Address: 1Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA, 2Department of Genetics, Southwest 
Foundation for Biomedical Research, San Antonio TX, USA, 3Division of Cardiology, Boston University School of Medicine, Boston MA, USA and 
4National Heart, Lung, and Blood Institute, Bethesda, MD, USA
Email: Patrick F McArdle - pmcardle@medicine.umaryland.edu; Sue Rutherford - srutherf@sfbrgenetics.org; 
Braxton D Mitchell - bmitchel@medicine.umaryland.edu; Coleen M Damcott - cdamcott@medicine.umaryland.edu; 
Ying Wang - ywang@medicine.umaryland.edu; Vasan Ramachandran - vasan@bu.edu; Sandy Ott - sott@som.umaryland.edu; Yen-
Pei C Chang - cchang@medicine.umaryland.edu; Daniel Levy - levyd@nhlbi.nih.gov; Nanette Steinle* - nsteinle@medicine.umaryland.edu
* Corresponding author    
Abstract
Background: Systemic blood pressure, influenced by both genetic and environmental factors, is
regulated via sympathetic nerve activity. We assessed the role of genetic variation in three subunits
of the neuromuscular nicotinic acetylcholine receptor positioned on chromosome 2q, a region
showing replicated evidence of linkage to blood pressure.
Methods: We sequenced CHRNA1, CHRND and CHRNG in 24 Amish subjects from the Amish
Family Diabetes Study (AFDS) and identified 20 variants. We then performed association analysis
of non-redundant variants (n = 12) in the complete AFDS cohort of 1,189 individuals, and followed
by genotyping blood pressure-associated variants (n = 5) in a replication sample of 1,759 individuals
from the Framingham Heart Study (FHS).
Results: The minor allele of a synonymous coding SNP, rs2099489 in CHRNG, was associated with
higher systolic blood pressure in both the Amish (p = 0.0009) and FHS populations (p = 0.009)
(minor allele frequency = 0.20 in both populations).
Conclusion: CHRNG is currently thought to be expressed only during fetal development. These
findings support the Barker hypothesis, that fetal genotype and intra-uterine environment influence
susceptibility to chronic diseases later in life. Additional studies of this variant in other populations,
as well as the effect of this variant on acetylcholine receptor expression and function, are needed
to further elucidate its potential role in the regulation of blood pressure. This study suggests for
the first time in humans, a possible role for genetic variation in the neuromuscular nicotinic
acetylcholine receptor, particularly the gamma subunit, in systolic blood pressure regulation.
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Hypertension is one of the most important risk factors for
cardiovascular disease, and end-stage renal disease. Glo-
bally hypertension is the leading risk factor for morbidity
and mortality [1], having multifactorial causal agents,
including genetic and environmental components. We
previously reported a genome wide scan of subjects from
the Amish Family Diabetes study that provided strong evi-
dence for linkage to diastolic (LOD = 3.36; p = 0.00004)
and systolic (LOD = 1.64; p = 0.003) blood pressure on
chromosome 2q31-q34 [2]. Follow-up analyses with
additional markers resulted in an increase in the LOD
score to 4.23 (p = 0.00001) for diastolic blood pressure
(Figure 1). Initial fine mapping of the region with a
densely spaced set of single nucleotide polymorphisms
(SNPs) showed association between several SNPs in
CHRND and systolic blood pressure (SBP). This region
also contains CHRNG and CHRNA1, which encode subu-
nits of the same nicotinic acetylcholine receptor that form
the neuromuscular nicotinic acetylcholine receptor.
Systemic blood pressure is tightly regulated through sym-
pathetic nerve activity. Feedback information about sys-
temic blood pressure is conveyed to the brainstem by
baroreceptor afferents. Accumulating evidence suggests
that perturbations in these neuronal mechanisms may
play a role in hypertension [3]. Indeed, hypertensive indi-
viduals tend to have increased sympathetic nerve activity
[4,5] and a functional change in the sensitivity of the
baroreceptor reflex [6]. In the spontaneously hypertensive
rat, abnormalities in cholinergic activity were shown to be
involved in the development of hypertension [7]. Nico-
tinic acetylcholine receptors play an important role in
processes involving regulation of systemic blood pressure
[7], and may also play an important role in neural devel-
opmental processes including cell differentiation, out-
growth and survival [8].
The nicotinic acetylcholine receptor has two main recep-
tor subtypes, the neuronal (ganglionic) receptor found in
the central nervous system and the neuromuscular recep-
tor found in the neuromuscular junction of somatic mus-
cle. The neuromuscular nicotinic acetylcholine receptor
Variance components linkage analysis of STR markers spaced approximately every 2 – 5 cM across the blood pressure linkage interval on chr mosome 2qFigure 1
Variance components linkage analysis of STR markers spaced approximately every 2 – 5 cM across the blood 
pressure linkage interval on chromosome 2q. LOD = 4.23 (p = 0.00001) for DBP; LOD = 1.60 (p = 0.003) for SBP.Page 2 of 10
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gamma subunit in fetal muscle or an epsilon subunit in
adults [9-11] Polymorphisms in the alpha and delta sub-
units have been shown to confer increased risk of
myasthenia gravis [12-15].
The gamma subunit of the nicotinic acetylcholine recep-
tor is reported to be important for neuromuscular devel-
opment [16] and ligand binding [17]. Disruption of the
gamma subunit, in vitro, prevents the correct localization
of the receptor in cell membranes [18]. The gamma subu-
nit contributes to neuromuscular signal transduction and
is also important for neuromuscular organogenesis
[16,19]. Rare mutations in CHRNG have been shown to
cause Escobar Syndrome, a condition manifested by
orthopedic and cranial anomalies [18,20].
To identify common genetic variants in the 3 nicotinic
acetylcholine receptor genes on chromosome 2q, each
gene was sequenced in 24 subjects enrolled in the Amish
Family Diabetes Study (AFDS). Variants were then geno-
typed in the entire AFDS sample and tested for association
with blood pressure levels. Associated variants were geno-
typed in an outbred Caucasian population from the Fram-
ingham Heart Study as a replication sample. To assess
whether associations relate to regulation by the postgan-
glionic nicotinic acetylcholine receptor, we genotyped
replicated variants in a second sample of Amish and tested
for association with response to a cold pressor stress test.
We provide the first evidence that a common genetic var-
iant in CHRNG is associated with systolic blood pressure.
Methods
Samples
Primary Amish Sample
Our principle sample consisted of Old Order Amish
(OOA) individuals from Lancaster County, PA. The OOA
are a genetically closed founder population originating
from Western Europe and who immigrated to central
Pennsylvania in the early 1700s [21]. They are particularly
well suited for genetic studies of complex diseases and
traits because they maintain a relatively uniform lifestyle
and tend not to use prescription medications. Family
members tend to eat meals together and the Amish diet is
largely similar across families. In addition, farming is still
the primary occupation and most OOA maintain a life-
style of high physical activity levels. The homogenous life-
style of the Amish reduces the variability of many
environmental influences and thereby enhances the
power to detect the genetic susceptibility to complex dis-
eases.
Our primary Amish sample consisted of 1,189 partici-
pants of the AFDS. The AFDS began in 1995 with the goal
of identifying susceptibility genes for type 2 diabetes and
related traits [22]. Probands were individuals identified
with type 2 diabetes and family members 18 years of age
and over were recruited into the study. The 1,189 individ-
uals recruited into the study were members of 226 pedi-
grees. The study protocol was performed either in the
individual's home or in the Amish Research Clinic in
Strasburg, Pennsylvania. Multiple phenotypes, including
blood pressure measurements, were obtained using a
standardized protocol. After the subject rested for at least
5 minutes, a single observer recorded systolic (first phase)
and diastolic (fifth phase) blood pressure (SBP and DBP
respectively) to the nearest mmHg in duplicate using a
standard sphygmomanometer.
The use of anti-hypertensive medication was <10%
among the AFDS subjects. We accounted for hypertension
medication use in two ways. First we performed the anal-
ysis using only those subjects who were not prescribed
anti-hypertension medication. This approach has the pos-
sibility of biasing the results because we are removing
those with the highest (untreated) blood pressures from
the analysis. Since the use of anti-hypertension medica-
tion is not as common in the Amish as the general popu-
lation, this bias is reduced. Second, we adjusted for
medication use by adding a constant to the observed
blood pressure measurements, 10 mmHg to SBP and 5
mmHg to DBP. This approach was suggested by Cui et. al.
[23] and later validated by Tobin et. al. [24].
Framingham Heart Study Sample
We genotyped BP-associated variants in a replication sam-
ple from an independent Caucasian population from
Framingham, MA. The Framingham Heart Study began in
1948 to investigate the causes of heart disease [25]. Men
and women (n = 5,209) between the ages of 28 and 62
years were recruited and followed prospectively over time.
Beginning in 1971, offspring of the original cohort were
recruited as part of the Framingham Offspring Study [26].
An additional 5,124 individuals were recruited for this
study, consisting of offspring and spouses of offspring of
the original cohort. Our sample consisted of 1,839 unre-
lated individuals who were randomly selected from the
Framingham Offspring Study as per the protocol estab-
lished by the collaboration between the National Heart,
Lung, and Blood Institute and Boston University. Each
participant underwent a physician administered exam
where blood pressure measurements were taken and a
DNA sample was collected. Data on blood pressure meas-
urements were collected every four years for members of
the offspring cohort. For the analysis in this report, we
used data from visits which took place from February
1995 to September 1998. The participants ranged in age
from 29 to 86 years at the time of this visit. Of the 1,839
randomly selected individuals, 1,759 have both a SBP and
DBP measurement recorded. Anti-hypertension medica-Page 3 of 10
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(29.6% in our sample) and was accounted for by the
methods described above.
Amish Sample – Cold Pressor Test
Variants associated with blood pressure in both the initial
Amish sample and the Framingham sample were geno-
typed in a second sample of Amish who were participants
of the Heredity and Phenotype Intervention (HAPI) Heart
Study. The HAPI Heart Study was initiated to identify
genes that interact with specific environmental exposures
to influence cardiovascular risk factors [27]. As part of this
study, we administered a 2.5-minute cold pressor test
(CPT) to 851 participants from 18 extended, Old Order
Amish families from Lancaster County, Pennsylvania. Of
the 851 participants of the CPT in the HAPI Heart Study,
149 were also participants of the AFDS. In the HAPI Heart
study, we utilized repeated blood pressure measurements
taken before, during, and after the CPT to derive physio-
logically relevant response traits such as reactivity to and
recovery from the cold pressor stimulus. Individuals
remained semi-reclined until their blood pressure was sta-
ble. The right hand and wrist to the ulnar styloid was sub-
merged in ice water for 2.5 minutes. Blood pressure and
heart rate were measured at 0, 1, 2, 3, 4, 5, 7.5, 10, 15, and
20 minutes by use of an appropriate fitting automated
blood pressure cuff. CPT reactivity was defined as the
change in blood pressure levels from baseline to 2 min-
utes after immersion. CPT recovery was defined as the
change in blood pressure from 2 minutes to 5 minutes
after immersion. The change in blood pressure (slope)
was calculated as sum((BP-mean(BP))(t-mean(t))/
sum((BP-mean(BP))2) for all non-missing blood pressure
measurements. All subjects were withdrawn from their
medications (only 2 subjects were on anti-hypertensive
medications) for 7 days prior to testing.
The Amish Studies and FHS were approved by respective
Institutional Review Boards, and conform to the Declara-
tion of Helsinki. All subjects provided informed consent.
DNA Sequencing and Genotyping
Genetic variants in CHRNA1, CHRND and CHRNG were
identified through direct sequencing of 24 non-first
degree relatives from the AFDS. This sequencing set pro-
vides 90% power to detect at least one copy of the minor
allele for single nucleotide polymorphisms (SNPs) with
allele frequencies of greater than or equal to 5%. We
sequenced all exons, splice junctions (~100 bp of the
intronic flanking sequence), and untranslated regions.
Both strands were sequenced on an ABI 3730 DNA
sequencer and analyzed using Sequencher V4.5 (Gene
Codes Corporation, Ann Arbor, MI). Initial sequencing
identified 20 variants, 4 of which were not annotated with
rs numbers in dbSNP and were subsequently not con-
firmed. (Sequence and primer information is available at
http://medschool.umaryland.edu/endocrinology/afd
spublic.asp. Follow the links "Publication List" and "Sup-
plemental Data.") Three SNPs (rs10629807, rs260068,
rs11674608) were in perfect linkage disequilibrium in the
sequencing set of 24 individuals with three other SNPs
identified (rs2646165, rs2646159, rs2697782 respec-
tively) and therefore represented redundant information.
Only the later set of SNPs were genotyped in the complete
sample. One SNP (rs2697782) failed our quality control
procedures. Thus genotypes for 12 SNPs were available for
association testing in the complete AFDS sample. Geno-
typing was carried out using the manufacturer's protocol
on the SNPstream Ultra High Throughput platform (Beck-
man Coulter, Fullerton, CA) and the Pyrosequencing PSQ
HS 96A system (Pyrosquencing, Uppsala, Sweden). The
genotype error rates based on blind replicates were 0 –
2%. All genotype frequencies conformed to Hardy-Wein-
berg expectations with the exception of rs3762528 (p =
0.02).
Statistical Methods
Analysis performed on the genotypes for the AFDS and
HAPI Heart Study utilized a variance component frame-
work, which modeled the genotype as a fixed effect and
controlled for sex, age and age squared. Each variant's
additive, dominant and recessive effects were estimated
using separate regression models. The variance compo-
nent approach models the correlations between the trait
of interest (the dependent variable) and dummy variables
coding the genotype effect (independent variable) condi-
tional on fixed covariates and the residual correlations
among individuals implied by the pedigree structure. Spe-
cifically, the covariance between each pair of individuals
within the pedigree was estimated as a function of their
degree of relationship, the trait heritability, and the phe-
notypic variance of the trait. The analysis was performed
using the SOLAR software package [28].
Simple linear regression was used to test for the associa-
tion between genotype and blood pressure in the Fram-
ingham sample. Three genetic models (additive,
dominant and recessive) were tested regardless of which
model was identified in the OOA.
An alpha level of < 0.01 was considered as strong evidence
of association.
Results
Sample Characteristics
Characteristics of the three samples are shown in Table 1.
The average age of the primary sample, the AFDS, was
49.4 years, while the mean age of the Framingham partic-
ipants was 59.4 years. The use of anti-hypertensive medi-
cation in the OOA sample was rare (9.3%) as compared toPage 4 of 10
(page number not for citation purposes)
BMC Medical Genetics 2008, 9:67 http://www.biomedcentral.com/1471-2350/9/67the population based sample from FHS (29.6%). The
AFDS sample contained 139 (11.7%) individuals with
diabetes. The participants in the HAPI Heart Study tended
to be younger (mean age = 43.6 years) and were relatively
more healthy (lower BMI and resting blood pressure)
than either the AFDS or FHS.
Linkage Disequilibrium Block Structure
Figure 2 shows the linkage disequilibrium (LD) plots for
variants genotyped in the complete AFDS sample. There is
little LD between the four SNPs in CHRNA1. CHRNG SNP
rs12996322 is correlated with rs6761667 (r2 = 0.70) and
in strong LD with CHRND SNP rs2767 (r2 = 0.88). SNPs
rs12996322 and rs2767 span the inter-genetic region
between CHRND and CHRNG. There is also significant
long range correlation between CHRND SNP rs2278478
and CHRNG SNP rs13018423 (r2 = 0.97), which are sepa-
rated by 16.8 kb.
Association with Blood Pressure
Table 2 shows the results from the association analysis to
blood pressure adjusted for age, sex and familial related-
ness in the AFDS sample. The values given are p-values for
the association analysis after removing those on anti-
hypertensive medication from the analysis. Very similar
results were found when accounting for medication in the
analysis as described in the methods (data not shown).
Evidence of association with blood pressure was present
for several variants including 6 variants whose most sig-
nificant model had strong evidence for association (p ≤
0.01) with either SBP or DBP (Table 2). As shown in Fig-
ure 2, these associations may not be independent signals
as some of the associated SNPs are in linkage disequilib-
rium.
Five BP-associated variants (rs2646159, rs3762528,
rs2767, rs12996322, and rs2099489) were genotyped in
the Framingham sample and association results are
shown in Table 3. The association with rs2099489 was the
only SNP showing significant association with blood pres-
sure in the Framingham sample. This SNP is a C -> T
(Arg474 -> Arg474) synonymous coding polymorphism in
the last exon of CHRNG.
Although not statistically significant, the rs2099489 SNP
was modestly associated with baseline SBP in the HAPI
Heart Study (p = 0.29). However, the allele associated
with higher mean SBP levels in AFDS and FHS was also
associated with higher mean SBP levels in HAPI. After tak-
ing into account individuals that were in both the AFDS
and HAPI cohorts, we combined the Amish samples and
found rs2099489 remained strongly associated with SBP
(p = 0.008). There was no association between rs2099489
and any of the response traits (change in blood pressure
during the reactivity time period, change in blood pres-
sure during recovery time period) to the cold pressor test.
Figure 3 shows the distribution of blood pressure by
rs2099489 genotypes in the AFDS, FHS and the HAPI
Heart Study samples. In both the OOA and FHS popula-
tions, the individuals with the TT genotype at SNP
rs2099489 have the highest age and sex adjusted residual
SBP. The TT genotype is associated with a 3 – 6 mmHg
increase in blood pressure over the age and sex predicted
values. This effect of 3 – 6 mmHg remained in each sam-
ple after adjusting for BMI which provides evidence that
rs2099489 is acting in pathways not mediated by body
mass.
Discussion
Evidence from animal models supports the role of the nic-
otinic acetylcholine receptor in blood pressure regulation
in the central nervous system. The potential role in blood
pressure regulation of acetylcholine receptors at the neu-
ral muscular junction remains to be elucidated. It has
been shown that spontaneously hypertensive rats, have a
lower number of nicotinic acetylcholine receptors in spi-
nal cord membranes than age-matched normotensive rats
[29] Furthermore, studies have shown rats with varying
blood pressure levels maintain relatively constant num-
Table 1: Sample characteristics for the AFDS, FHS, and the HAPI Heart Study.
AFDS FHS HAPI
N 1189 1759 851
Sex (% male) 45.3% 49.6% 53.2%
Mean (SD) age (yrs) 49.4 ± 17.1 59.4 ± 9.4 43.6 ± 13.9
Mean (SD) BMI (kg/m2) 27.2 ± 5.0 28.0 ± 5.1 26.7 ± 4.5
Hypertension medication use (%) 9.3% 29.6% *
Mean (SD) SBP/DBP (mmHg) 122.2 ± 15.9 125.5 ± 17.4 116.5 ± 13.3
Those on medication removed 77.7 ± 9.6 74.8 ± 9.1 70.6 ± 7.5
Mean (SD) SBP/DBP (mmHg) 125.2 ± 18.9 132.4 ± 20.8 *
Constant added to those on medication 78.5 ± 10.2 77.0 ± 10.0
* Anti-hypertension medications were withdrawn 7 days prior to testing and therefore no HAPI subjects were on medications at the time of study.Page 5 of 10
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Linkage disequilibrium block structure for CHRNA1, CHRND and CHRNG in the Old Order AmishFigur 2
Linkage disequilibrium block structure for CHRNA1, CHRND and CHRNG in the Old Order Amish. Values given 
are r-squared times 100.
Table 2: Association analysis of polymorphisms in CHRNA1, CHRND and CHRNG with blood pressure in the AFDS.
Marker Polymorphism Minor Allele Frequency Mean SBP/DBP By Genotype (mmHg) P-Value
Homozygous for major 
allele
Heterozygous Homozygous for minor 
allele
SBP DBP
CHRNA1
rs2646159 Intron 2 0.09 122/77 122/79 132/91 0.14 0.009
rs2305416 Exon 7: His320His 0.06 123/78 123/77 134/79 0.09 0.70
rs2646165 Intron 4 0.14 123/76 123/79 124/81 0.24 0.07
rs7560774 Intron 1 0.46 122/79 122/77 123/77 0.23 0.04
CHRND
rs2278478 Intron 2 0.29 122/77 123/78 123/80 0.32 0.45
rs3762528 Intron 9 0.09 121/77 126/79 113/78 0.0007 0.18
rs2767 Exon 12 UTR 0.43 121/79 125/80 128/81 0.0007 0.05
CHRNG
rs12996322 Intron 1 0.41 120/77 124/78 126/79 0.007 0.26
rs6761667 Intron 6 0.48 119/76 123/78 125/78 0.0001 0.007
rs2573206 Intron 8 0.19 120/77 121/77 123/78 0.03 0.04
rs13018423 Intron 8 0.29 122/77 123/78 125/78 0.31 0.63
rs2099489 Exon 12: Arg474Arg 0.20 121/77 124/78 127/78 0.0009 0.02
Values given are p-values from the most significant genetic model (additive, dominant, recessive), controlling for age and sex. Results are given after 
removing those on antihypertensive medication from the analysis.
BMC Medical Genetics 2008, 9:67 http://www.biomedcentral.com/1471-2350/9/67bers of nicotinic receptors. This indicates that blood pres-
sure does not drive receptor number but rather that the
lower receptor number might be a primary event in hyper-
tension [30].
We investigated the association between blood pressure
regulation and genetic polymorphisms in genes encoding
three subunits of the neuromuscular nicotinic acetylcho-
line receptor located on chromosome 2q. We demon-
strated significant association with DBP and genetic
variation in CHRNA1 and between SBP and several poly-
morphisms in CHRND and CRHNG in OOA subjects
from the AFDS. However, blood pressure-associated vari-
ants in CHRNA1 and CHRND were not replicated in a
sample from the Framingham Heart Study, perhaps indi-
cating that these associations were false positive signals or,
less likely, that these variants are only relevant to blood
pressure determinants in the Amish. By contrast, we did
demonstrate replication of the association of the CHRNG
SNP rs2099489 with SBP. The replicated rs2099489 is a C-
> T synonymous coding SNP in the last exon of the
gamma subunit of the nicotinic acetylcholine receptor. In
our Caucasian populations, the TT genotype at this locus
was associated with 3–6 mmHg higher SBP than age and
sex predicted values. A trend with a similar effect size for
association between SBP and rs2099489 was detected in
an independent OOA cohort from the HAPI Heart Study.
Although not of statistical significance in the HAPI cohort,
the fact that the subjects are on average younger and
healthier than subjects in the AFDS may influence the
association result for rs2099489 in this cohort. To place
our findings in the context of potential impact on general
health, we estimated the change in 10 year risk of myocar-
dial infarction or death using the Framingham Risk score
calculator available online through the National Heart,
Lung, and Blood Institute http://hp2010.nhlbihin.net/
atpiii/calculator.asp. For a man age 55 years or older, or a
woman age 65 or older who has normal cholesterol and
does not use tobacco and is not currently taking medica-
tion to lower blood pressure, each incremental rise in SBP
of 5 mm Hg would increase the 10 year Framingham Risk
of myocardial infarction or death by approximately 1%.
Although the polymorphism we identified is synony-
mous, it may influence expression by altering pre mRNA
splicing, mRNA stability, or efficiency of translation [31].
Alternatively, rs2099489 may not be causative but rather
may be in linkage disequilibrium with a causative, as yet,
ungenotyped polymorphism. While this is possible, it is
unlikely that such a polymorphism exists in a coding
region since all exons were sequenced. Further, it is possi-
ble that the association identified is a false positive. One
reason for false positives is population stratification and is
unlikely to be a significant concern in this study because
we are using relatively homogenous Caucasian popula-
tions, particularly the Amish, whose ancestry since emi-
gration to the New World is well characterized. The
replication of our findings for rs2099489 in two distinct
populations is further evidence against a false positive
finding.
Hales and Barker posed the notion that fetal genotype and
intra-uterine environment influence susceptibility to
chronic diseases later in life [32]. Our findings are consist-
ent with this hypothesis, demonstrating association
between genetic variation in a gene expressed during
embryogenesis and adult hypertension. Additional work
will be necessary to discern how this receptor subunit, cur-
rently understood to be expressed during fetal develop-
ment, impacts blood pressure in adulthood. It is also
possible that this receptor may be expressed during adult-
hood at levels that are below current detection thresholds,
or expressed transiently during periods of metabolic
stress. Neoteric models to test these hypotheses will need
to be developed to further our understanding of the role
of CHRNG in blood pressure regulation.
Conclusion
Our study suggests for the first time in humans, a possible
role for genetic variation in the neuromuscular nicotinic
acetylcholine receptor, particularly the gamma subunit, in
Table 3: Replication of association in a sample of Caucasians enrolled in the FHS.
Marker Minor Allele Frequency Mean SBP/DBP By Genotype (mmHg) P-Value
Homozygous for major allele Heterozygous Homozygous for minor allele SBP DBP
rs2646159 0.07 126/75 124/75 127/68 0.12 0.14
rs3762528 0.06 125/75 127/75 137/81 0.30 0.25
rs2767 0.36 126/75 125/75 125/74 0.24 0.72
rs12996322 0.36 125/75 126/75 126/74 0.11 0.53
rs2099489 0.20 125/75 125/75 133/75 0.009 0.25
* Values given are p-values from the most significant genetic model (additive, dominant, recessive), controlling for age and sex. Results are given 
after removing those on antihypertensive medication from the analysis.Page 7 of 10
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Mean of age and sex adjusted residual blood pressure by rs2099489 genotype for the AFigure 3
Mean of age and sex adjusted residual blood pressure by rs2099489 genotype for the A. Amish Family Diabetes 
Study; B. the Framingham Heart Study; and C. the Heredity And Phenotype Intervention (HAPI) Heart 
Study. SBP residual in solid bars, DBP residual in hatched bars. Standard error is represented by vertical lines.
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BMC Medical Genetics 2008, 9:67 http://www.biomedcentral.com/1471-2350/9/67SBP regulation. Additional analyses of these polymor-
phisms in other ethnic populations, as well as studies of
the effect of genetic polymorphisms on expression and
function of this nicotinic acetylcholine receptor are
needed to further elucidate its potential role in the regula-
tion of blood pressure.
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